Physician profile
Jason T Su
NPI 1427137991
$894.48
in general payments reported to CMS, 2019-2025
18 companies · $97.79 in 2025
The $97.79 reported for 2025 was less than what a typical Pediatric Cardiology provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.34 · 2021: $139 · 2022: $236 · 2023: $197 · 2024: $208 · 2025: $97.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $130.23 | 2021-2024 | Tremfya |
| Cmp Pharma, INC. | $82.92 | 2022-2023 | Tadliq, Norliqva, Carospir |
| Amgen INC. | $72.38 | 2021-2023 | Amjevita |
| Ucb, INC. | $68.23 | 2022-2025 | Bimzelx |
| Mallinckrodt Hospital Products INC. | $67.54 | 2022-2023 | Acthar |
| Ani Pharmaceuticals, INC. | $65.59 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $54.87 | 2021 | |
| Novartis Pharmaceuticals Corporation | $52.95 | 2023-2025 | |
| Baxter Healthcare | $49.43 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $45.50 | 2022-2024 | |
| Abbvie INC. | $39.56 | 2021-2023 | Synthroid |
| Ibsa Pharma INC. | $38.91 | 2023-2024 | Tirosint, Licart, Licart |
| Shorla Oncology INC. | $34.09 | 2024 | |
| Sobi, INC | $22.89 | 2021 | |
| Mylan Institutional INC. | $20.81 | 2023 | Hulio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18.15 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.34 | 2020 | |
| Genentech USA, INC. | $14.09 | 2025 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.